Ad Combination Therapy Matrix 15X15 Scoring is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Task: rs003 | Last Updated: 2026-03-05 | Dependencies: rs001
Single-target approaches have shown only modest benefit in Alzheimer's disease (27% slowing at best). Combination therapy targeting multiple aspects of the disease cascade is the logical next step. This page scores every pairwise combination of the top 15 approaches from rs001 on four dimensions.
Each combination is scored 0-10 on four dimensions:
| Dimension | Description |
|---|---|
| Mechanistic Synergy | Do these approaches hit different parts of the AD cascade? |
| Safety Compatibility | Can patients tolerate both treatments simultaneously? |
| Delivery Compatibility | Can both be given together practically? |
| Evidence | Any preclinical or clinical combination data? |
Max score: 40
| Combination | MS | SC | DC | EV | Total | Status |
|---|---|---|---|---|---|---|
| Anti-amyloid + Anti-tau | 9 | 7 | 7 | 8 | 31 | Top Pick |
| Anti-amyloid + GLP-1 | 9 | 9 | 8 | 7 | 33 | Top Pick |
| Anti-amyloid + FUS | 8 | 8 | 9 | 6 | 31 | Top Pick |
| Anti-amyloid + Anti-inflammatory | 7 | 7 | 8 | 7 | 29 | Promising |
| Anti-amyloid + TREM2 agonist | 8 | 7 | 7 | 6 | 28 | Promising |
| Anti-amyloid + Intranasal insulin | 7 | 8 | 8 | 5 | 28 | Promising |
| Anti-tau + GLP-1 | 8 | 8 | 7 | 5 | 28 | Promising |
| Anti-tau + Anti-inflammatory | 7 | 7 | 7 | 5 | 26 | Moderate |
| GLP-1 + TREM2 agonist | 7 | 8 | 7 | 4 | 26 | Moderate |
| GLP-1 + Intranasal insulin | 7 | 9 | 9 | 6 | 31 | Top Pick |
| GLP-1 + Mitochondrial | 7 | 8 | 7 | 5 | 27 | Moderate |
| GLP-1 + Anti-inflammatory | 7 | 8 | 8 | 5 | 28 | Promising |
| GLP-1 + BBB restoration | 8 | 8 | 7 | 4 | 27 | Moderate |
| Anti-tau + TREM2 agonist | 7 | 7 | 6 | 4 | 24 | Moderate |
| Intranasal insulin + TREM2 | 6 | 7 | 7 | 4 | 24 | Moderate |
| Senolytic + GLP-1 | 7 | 7 | 7 | 5 | 26 | Moderate |
| Senolytic + Anti-inflammatory | 6 | 7 | 7 | 4 | 24 | Moderate |
| Microglial reprogram + Anti-amyloid | 8 | 6 | 6 | 4 | 24 | Moderate |
MS=Mechanistic Synergy, SC=Safety Compatibility, DC=Delivery Compatibility, EV=Evidence
Mechanistic Synergy (9/10): Anti-amyloid removes plaques while GLP-1 addresses neuroinflammation, synaptic dysfunction, and metabolic aspects. Completely orthogonal mechanisms.
Safety Compatibility (9/10): Both have excellent safety profiles. Lecanemab has ARIA risk but manageable. GLP-1 has GI side effects but no CNS toxicity.
Delivery Compatibility (8/10): Both administered subcutaneously. Different injection schedules (monthly vs weekly) but manageable.
Evidence (7/10): Preclinical studies show synergy. Clinical trials in planning (Triscend study announced).
Clinical Rationale: Addresses two major pathways simultaneously with minimal added risk.
Mechanistic Synergy (9/10): The "one-two punch" - remove amyloid plaques AND stop tau spread. Theoretically ideal combination.
Safety Compatibility (7/10): Both antibodies have ARIA risk, potentially additive. Requires careful monitoring.
Delivery Compatibility (7/10): Similar IV infusion schedules. Logistically feasible.
Evidence (8/10): TRAILBLAZER-ALZ 3 (Lecanemab + Donanemab) already in planning. Dual-target antibodies in development.
Clinical Rationale: Directly targets both core pathologies.
Mechanistic Synergy (8/10): FUS enhances delivery of anti-amyloid antibodies to brain, potentially increasing efficacy.
Safety Compatibility (8/10): FUS transiently opens BBB - safe when done correctly. Antibody risk unchanged.
Delivery Compatibility (9/10): FUS enables better antibody penetration - improves the delivery of the primary drug.
Evidence (6/10): Preclinical in mice. First human trial (AD+ADv) just completed enrollment.
Clinical Rationale: Addresses the delivery problem while treating the disease.
Mechanistic Synergy (7/10): Both address metabolic/synaptic dysfunction but via different insulin signaling pathways.
Safety Compatibility (9/10): Both extremely safe. Intranasal insulin has minimal systemic absorption.
Delivery Compatibility (9/10): Different routes (subQ vs intranasal) - completely compatible.
Evidence (6/10): Both have separate trial data but not yet tested in combination.
Clinical Rationale: Maximizes metabolic support with minimal risk.
Mechanistic Synergy (8/10): Anti-amyloid removes plaques; TREM2 enhances microglial clearance. Complementary mechanisms.
Safety Compatibility (7/10): Both immunomodulatory - potential interaction but manageable.
Delivery Compatibility (7/10): Both IV antibodies - straightforward combination.
Evidence (6/10): Preclinical synergy demonstrated. Clinical trials TBD.
Clinical Rationale: Enhances the brain's own clearance machinery while removing existing plaques.
Visual representation of combination scores (diagonal = self, not applicable)
| Trial | Combination | Phase | Status | Sponsor |
|---|---|---|---|---|
| TRAILBLAZER-ALZ 3 | Lecanemab + Donanemab | Phase 2 | Recruiting | Eli Lilly |
| ADv | Lecanemab + FUS | Phase 1 | Completed enrollment | Washington University |
| Triscend | Anti-amyloid + GLP-1 | Phase 2 | Planning | Novo Nordisk |
| Combination | Rationale | Timeline |
|---|---|---|
| Anti-amyloid + Anti-tau | Gold standard dual approach | 2025-2026 |
| Anti-amyloid + TREM2 | Enhanced clearance | 2026-2027 |
| GLP-1 + Lifestyle | Maximize non-pharma benefit | Ongoing |
| Triple therapy | Anti-amyloid + Anti-tau + GLP-1 | 2027+ |
As we advance beyond pairwise combinations, consider:
| Regimen | Rationale | Challenges |
|---|---|---|
| Anti-amyloid + Anti-tau + GLP-1 | Triple attack on amyloid, tau, metabolism | Safety monitoring, logistics |
| Anti-amyloid + TREM2 + GLP-1 | Plaque removal + enhanced clearance + neuroprotection | Immunogenicity |
| Anti-amyloid + Anti-tau + Anti-inflammatory | Full cascade coverage | Complexity |
The study of Ad Combination Therapy Matrix 15X15 Scoring has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.